ReviewCurrent drug targets2024
Drug Repurposing Using FDA Adverse Event Reporting System (FAERS) Database.
Review in Current drug targets, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 31 citations in OpenAlex.
- Adverse events associated with immune checkpoint inhibitors in combination with chemotherapy in lung cancer: a real-world analysis.Journal of thoracic disease · 2026Article
- Agent-specific bleeding signatures in non-hypertensive versus hypertensive patients exposed to oral anticoagulants: a real-world pharmacovigilance study.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Deciphering the Formulation-Dependent Neurotoxicity of Irinotecan: An Integrated Pharmacovigilance and Mechanistic Study.Journal of biochemical and molecular toxicology · 2026Article
- Disproportionality Analysis of Breast Cancer-Related Reports Across Vitamin K Homologs in the FDA Adverse Event Reporting System.Pharmaceuticals (Basel, Switzerland) · 2026Article
- When Side Effects Become Therapies: A Mechanistic Taxonomy of Adverse Drug Reactions as Translational Signals for Drug Repositioning.Fundamental & clinical pharmacology · 2026Review
- Safety evaluation of CD3×CD20 bispecific antibodies: a pharmacovigilance study using FDA adverse event reporting system.BMJ open · 2026Article
- An intelligent drug supply chain management and recommendation framework using blockchain and TRPO-driven multi-agent learning.Scientific reports · 2026Article
- Integrating Pharmacovigilance Data Mining and Mendelian Randomization to Identify Risk Profiles and Causal Targets of Opioid-Induced Delirium.CNS neuroscience & therapeutics · 2026Article
- Rethinking bioinformatics in liquid-liquid phase separation: data resources, predictive models, and an event-centric perspective.Briefings in bioinformatics · 2026Review
- Signals of Drug-Related Retinal Fibrosis: Findings From a 20-Year Disproportionality Analysis of Global Spontaneous Reports.Translational vision science & technology · 2026Article
- Post-marketing safety profile of cladribine in multiple sclerosis: a disproportionality analysis based on the FDA adverse event reporting system.International journal of clinical pharmacy · 2026Article
- Adverse event of ACE inhibitors: A descriptive analysis of FAERS data.Journal of public health research · 2026Article
- Thrombocytopenia and anemia associated with piperacillin-tazobactam: integrating clinical case series with FAERS disproportionality analysis.Frontiers in pharmacology · 2026Article
- Real‑world safety evaluation of tranexamic acid: Signal detection from FAERS and VigiAccess databases.PloS one · 2026Article
- Beyond adrenal suppression: a comprehensive post-marketing safety profile of etomidate from real world data.Frontiers in medicine · 2026Article
- Drug-associated inflammatory bowel disease: a real-world pharmacovigilance study using the FAERS and JADER databases.Frontiers in immunology · 2026Article
- Adverse Event Profiles of Monoclonal Antibodies: A Descriptive Analysis of FAERS Data.Health services insights · 2026Article
- Potential heterogeneity of epcoritamab associated adverse events in demographics and dosing regimens.Frontiers in medicine · 2026Article
- Article
- Drug-induced intestinal obstruction: insights from the FDA Adverse Event Reporting System.Therapeutic advances in drug safety · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Drug repurposing is an emerging approach to reassigning existing pre-approved therapies for new indications. The FDA Adverse Event Reporting System (FAERS) is a large database of over 28 million adverse event reports submitted by medical providers, patients, and drug manufacturers and provides extensive drug safety signal data. In this review, four common drug repurposing strategies using FAERS are described, including inverse signal detection for a single disease, drug-drug interactions that mitigate a target ADE, identifying drug-ADE pairs with opposing gene perturbation signatures and identifying drug-drug pairs with congruent gene perturbation signatures. The purpose of this review is to provide an overview of these different approaches using existing successful applications in the literature. With the fast expansion of adverse drug event reports, FAERS-based drug repurposing represents a promising strategy for discovering new uses for existing therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.